Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ABMD's Cash to Debt is ranked higher than
89% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. ABMD: No Debt )
ABMD' s 10-Year Cash to Debt Range
Min: 31.75   Max: No Debt
Current: No Debt

Equity to Asset 0.81
ABMD's Equity to Asset is ranked higher than
85% of the 447 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ABMD: 0.81 )
ABMD' s 10-Year Equity to Asset Range
Min: 0.69   Max: 0.94
Current: 0.81

0.69
0.94
Interest Coverage No Debt
ABMD's Interest Coverage is ranked higher than
99% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 231.38 vs. ABMD: No Debt )
ABMD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 8
Z-Score: 22.80
M-Score: -2.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 5.53
ABMD's Operating margin (%) is ranked higher than
75% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. ABMD: 5.53 )
ABMD' s 10-Year Operating margin (%) Range
Min: -111.48   Max: 10.46
Current: 5.53

-111.48
10.46
Net-margin (%) 5.14
ABMD's Net-margin (%) is ranked higher than
77% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. ABMD: 5.14 )
ABMD' s 10-Year Net-margin (%) Range
Min: -84.54   Max: 9.5
Current: 5.14

-84.54
9.5
ROE (%) 6.15
ABMD's ROE (%) is ranked higher than
76% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. ABMD: 6.15 )
ABMD' s 10-Year ROE (%) Range
Min: -46.87   Max: 11.4
Current: 6.15

-46.87
11.4
ROA (%) 5.06
ABMD's ROA (%) is ranked higher than
79% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. ABMD: 5.06 )
ABMD' s 10-Year ROA (%) Range
Min: -42.19   Max: 9.27
Current: 5.06

-42.19
9.27
ROC (Joel Greenblatt) (%) 55.48
ABMD's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. ABMD: 55.48 )
ABMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -294.77   Max: 90.23
Current: 55.48

-294.77
90.23
Revenue Growth (%) 17.50
ABMD's Revenue Growth (%) is ranked higher than
92% of the 341 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. ABMD: 17.50 )
ABMD' s 10-Year Revenue Growth (%) Range
Min: -7.2   Max: 26.3
Current: 17.5

-7.2
26.3
» ABMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ABMD Guru Trades in Q4 2013

PRIMECAP Management 5,751,990 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons 79,323 sh (-69.55%)
» More
Q1 2014

ABMD Guru Trades in Q1 2014

Joel Greenblatt 25,692 sh (New)
Paul Tudor Jones 11,200 sh (New)
Steven Cohen 11,972 sh (New)
PRIMECAP Management 5,751,990 sh (unchged)
Jim Simons Sold Out
» More
Q2 2014

ABMD Guru Trades in Q2 2014

Jim Simons 97,223 sh (New)
Chase Coleman 1,690,000 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 5,726,490 sh (-0.44%)
» More
Q3 2014

ABMD Guru Trades in Q3 2014

Chase Coleman 1,690,000 sh (unchged)
Jim Simons Sold Out
PRIMECAP Management 5,664,990 sh (-1.07%)
» More
» Details

Insider Trades

Latest Guru Trades with ABMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Sold Out 0.01%$20.87 - $26.2 $ 37.0660%0
Joel Greenblatt 2014-03-31 New Buy0.01%$25.6 - $30.03 $ 37.0634%25692
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 150.00
ABMD's P/E(ttm) is ranked higher than
72% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 85.90 vs. ABMD: 150.00 )
ABMD' s 10-Year P/E(ttm) Range
Min: 36.46   Max: 946.92
Current: 150

36.46
946.92
P/B 8.50
ABMD's P/B is ranked higher than
55% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.88 vs. ABMD: 8.50 )
ABMD' s 10-Year P/B Range
Min: 1.58   Max: 8.54
Current: 8.5

1.58
8.54
P/S 8.10
ABMD's P/S is ranked higher than
59% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.41 vs. ABMD: 8.10 )
ABMD' s 10-Year P/S Range
Min: 2.38   Max: 10.62
Current: 8.1

2.38
10.62
PFCF 61.30
ABMD's PFCF is ranked higher than
82% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABMD: 61.30 )
ABMD' s 10-Year PFCF Range
Min: 23.56   Max: 2462
Current: 61.3

23.56
2462
EV-to-EBIT 130.28
ABMD's EV-to-EBIT is ranked higher than
70% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 64.69 vs. ABMD: 130.28 )
ABMD' s 10-Year EV-to-EBIT Range
Min: -305.5   Max: 694.7
Current: 130.28

-305.5
694.7
Current Ratio 4.99
ABMD's Current Ratio is ranked higher than
85% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. ABMD: 4.99 )
ABMD' s 10-Year Current Ratio Range
Min: 3.18   Max: 15.95
Current: 4.99

3.18
15.95
Quick Ratio 4.49
ABMD's Quick Ratio is ranked higher than
87% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. ABMD: 4.49 )
ABMD' s 10-Year Quick Ratio Range
Min: 2.56   Max: 15.43
Current: 4.49

2.56
15.43

Valuation & Return

vs
industry
vs
history
Price/Net Cash 27.04
ABMD's Price/Net Cash is ranked higher than
86% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABMD: 27.04 )
ABMD' s 10-Year Price/Net Cash Range
Min: 1.29   Max: 73.96
Current: 27.04

1.29
73.96
Price/Net Current Asset Value 18.91
ABMD's Price/Net Current Asset Value is ranked higher than
81% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABMD: 18.91 )
ABMD' s 10-Year Price/Net Current Asset Value Range
Min: 1.16   Max: 409.4
Current: 18.91

1.16
409.4
Price/Tangible Book 12.36
ABMD's Price/Tangible Book is ranked higher than
61% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.71 vs. ABMD: 12.36 )
ABMD' s 10-Year Price/Tangible Book Range
Min: 1   Max: 16.93
Current: 12.36

1
16.93
Price/DCF (Projected) 6.55
ABMD's Price/DCF (Projected) is ranked higher than
81% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABMD: 6.55 )
ABMD' s 10-Year Price/DCF (Projected) Range
Min: 4.39   Max: 41.45
Current: 6.55

4.39
41.45
Price/Median PS Value 1.28
ABMD's Price/Median PS Value is ranked higher than
69% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. ABMD: 1.28 )
ABMD' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 4.3
Current: 1.28

0.38
4.3
Price/Graham Number 9.00
ABMD's Price/Graham Number is ranked higher than
75% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABMD: 9.00 )
ABMD' s 10-Year Price/Graham Number Range
Min: 2.97   Max: 15.85
Current: 9

2.97
15.85
Earnings Yield (Greenblatt) 0.80
ABMD's Earnings Yield (Greenblatt) is ranked higher than
69% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ABMD: 0.80 )
ABMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3.7
Current: 0.8

0.1
3.7

Analyst Estimate

Mar15 Mar16 Mar17 Mar18
Revenue(Mil) 212 258 312 374
EPS($) 0.22 0.58 1.51 2.08
EPS without NRI($) 0.22 0.58 1.51 2.08

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:AIO.Germany,
Abiomed Inc is a Delaware corporation incorporated on June 4, 1987. The Company is engaged in providing mechanical circulatory support devices and it offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Companys product portfolio includes; Impella 2.5, Impella CP, Impella RP, AB5000, Symphony, and Impella 5.0 & Impella LD. The Companys Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors for use mainly in interventional cardiology. The device is designed mainly for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain their circulation. The Impella 5.0 catheter and Impella LD are percutaneous micro heart pumps with integrated motors and sensors for use mainly in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support as compared to the Impella 2.5. The Impella RP is a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute and to provide the flow and pressure needed to compensate for right heart failure. The Company manufactures & sells the AB5000 Circulatory Support System for the temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. The Company faces competition from Getinge (Maquet Cardiovascular), Teleflex Inc., Thoratec Corporation, HeartWare International Inc., Jarvik Heart, Terumo Heart, Inc. and CardiacAssist Inc. The Companys business is subject to extensive federal, state, local and foreign regulation.
» More Articles for ABMD

Headlines

Articles On GuruFocus.com
Vycor Value Could be Unlocked with These Major Partnerships Dec 05 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Weekly CFO Sells Highlight: BDSI, LNKD, VRSK, ABMD, AGX Jul 17 2012 
ABIOMED Inc. Reports Operating Results (10-Q) Feb 04 2011 
ABIOMED Inc. Reports Operating Results (10-Q) Aug 05 2010 
ABIOMED Inc. (ABMD) COO David M Weber sells 1,389 Shares May 25 2010 
ABIOMED Inc. (ABMD) President, CEO, Chairman Michael R Minogue sells 4,491 Shares May 25 2010 
Trade Setups for May 19, 2010 May 19 2010 
Trade Setups for May 17, 2010 May 17 2010 

More From Other Websites
Nasdaq stocks posting largest percentage increases Dec 18 2014
Abiomed to Present at the Piper Jaffray 26th Annual Healthcare Conference Nov 26 2014
Abiomed to Present at the Piper Jaffray 26th Annual Healthcare Conference Nov 26 2014
Abiomed and Area Colleges to Host Life Sciences Career Seminars for Growing Number of Student... Nov 24 2014
Abiomed and Area Colleges to Host Life Sciences Career Seminars for Growing Number of Student... Nov 20 2014
ABIOMED INC Financials Nov 19 2014
Abiomed to Present at the Jefferies 2014 Global Healthcare Conference Nov 17 2014
ABIOMED (ABMD) Stock: Moving Average Crossover Alert Nov 13 2014
10-Q for ABIOMED, Inc. Nov 12 2014
Abiomed (ABMD) Hits 52-Week High on Strong Q2 Results Nov 12 2014
ABIOMED INC Files SEC form 10-Q, Quarterly Report Nov 10 2014
Medical-Device Stocks Could Benefit From Tax Repeal Nov 05 2014
Abiomed Tops Q2 Earnings, Revenues; FY15 Sales View Up Nov 04 2014
Ocwen Financial Climbs Despite Earnings Shortfall Oct 30 2014
ABIOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 30 2014
Abiomed tops Street 2Q forecasts Oct 30 2014
Abiomed tops Street 2Q forecasts Oct 30 2014
Abiomed Announces Second Quarter Fiscal 2015 Revenue of $51.9 Million, Up 17% Over Prior Year Oct 30 2014
Q2 2015 Abiomed Inc Earnings Release - Before Market Open Oct 30 2014
Abiomed Announces Second Quarter Fiscal 2015 Revenue of $51.9 Million, Up 17% Over Prior Year Oct 30 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK